Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Should we use apoB for risk assessment and as a target for treatment?

Brown WV, Myers GL, Sniderman AD, Stein E.

J Clin Lipidol. 2010 May-Jun;4(3):144-51. doi: 10.1016/j.jacl.2010.03.004. Epub 2010 Mar 16. No abstract available.

PMID:
21122646
2.

Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?

Sniderman A, McQueen M, Contois J, Williams K, Furberg CD.

J Clin Lipidol. 2010 May-Jun;4(3):152-5. doi: 10.1016/j.jacl.2010.03.005. Epub 2010 Mar 18. Review.

PMID:
21122647
3.

Apolipoprotein B (apoB) more closely related to subclinical atherosclerosis than non-HDL cholesterol and LDL cholesterol.

Walldius G.

J Intern Med. 2010 Dec;268(6):549-51. doi: 10.1111/j.1365-2796.2010.02286.x. No abstract available.

4.

Apolipoprotein B versus LDL-cholesterol: Association with other risk factors for atherosclerosis.

Vaverkova H, Karasek D, Novotny D, Jackuliakova D, Lukes J, Halenka M, Frohlich J.

Clin Biochem. 2009 Aug;42(12):1246-51. doi: 10.1016/j.clinbiochem.2009.05.004. Epub 2009 May 18.

PMID:
19450572
6.

Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.

Walldius G, Jungner I.

Nutr Metab Cardiovasc Dis. 2007 Oct;17(8):565-71. Epub 2007 Jul 16.

PMID:
17631989
7.

[Apolipoproteins are new and better risk indicators of myocardial infarction].

Walldius G, Jungner I.

Lakartidningen. 2004 Mar 25;101(13):1188-94. Review. Swedish.

PMID:
15101244
8.

Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges.

Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR.

Circulation. 2013 Sep 10;128(11):1256-67. doi: 10.1161/CIRCULATIONAHA.113.000962. Review. No abstract available.

9.

[The apoB/apoA-I ratio is better myocardial infarction marker than lipids].

Walldius G, Angelin B, Eriksson M.

Lakartidningen. 2006 Mar 8-14;103(10):751-2. Review. Swedish. No abstract available.

PMID:
16610201
10.

Apolipoprotein measurements: is more widespread use clinically indicated?

Davidson MH.

Clin Cardiol. 2009 Sep;32(9):482-6. doi: 10.1002/clc.20559. Review.

11.

Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk.

Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J.

J Intern Med. 2010 Dec;268(6):567-77. doi: 10.1111/j.1365-2796.2010.02277.x.

12.

[The use of apolipoprotein B in clinical practice to determine the risk for atherosclerosis].

Cabezas Castro M, Liem A.

Ned Tijdschr Geneeskd. 2003 Jul 26;147(30):1445-8. Review. Dutch.

PMID:
12908345
13.

Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.

Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H.

Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2615-22. Epub 2005 Sep 29.

15.

Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment.

Davidson MH.

Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1582-3. doi: 10.1161/ATVBAHA.108.172718. No abstract available.

16.

[Semiologic value of LDL cholesterol and apolipoprotein B in risk of atherosclerosis].

Frey J, Couderc R.

Ann Biol Clin (Paris). 1998 Sep-Oct;56(5):517-20. French. No abstract available.

17.

Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS).

Williams K, Sniderman AD, Sattar N, D'Agostino R Jr, Wagenknecht LE, Haffner SM.

Circulation. 2003 Nov 11;108(19):2312-6. Epub 2003 Oct 27.

18.

Apolipoproteins as markers and managers of coronary risk.

Chan DC, Watts GF.

QJM. 2006 May;99(5):277-87. Epub 2006 Feb 27. Review. Erratum in: QJM. 2006 Nov;99(11):807.

PMID:
16504986
19.
20.

Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?

Manfroi WC, Zago AJ, Campos M, Alves A, Brisolara ML, de Souza J, Candiago RH, Kirschnick L, Ribeiro L, Ordovás K, Leitão C, Cruz R.

Arq Bras Cardiol. 1999 Jun;72(6):657-68. English, Portuguese.

PMID:
10752172

Supplemental Content

Support Center